Helikon Investments Ltd Purchases Shares of 78,010 Grifols, S.A. (NASDAQ:GRFS)

Helikon Investments Ltd acquired a new position in shares of Grifols, S.A. (NASDAQ:GRFS) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 78,010 shares of the biotechnology company’s stock, valued at approximately $580,000. Grifols makes up about 0.1% of Helikon Investments Ltd’s portfolio, making the stock its 19th largest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its stake in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 1,135 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Grifols by 66.2% in the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 2,153 shares during the period. Blue Trust Inc. raised its holdings in Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares during the period. AQR Capital Management LLC bought a new stake in Grifols in the second quarter worth $89,000. Finally, HighTower Advisors LLC boosted its stake in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,546 shares during the period.

Grifols Stock Performance

Shares of NASDAQ GRFS opened at $7.35 on Monday. The firm has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.19. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $9.96. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Analysts Set New Price Targets

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research note on Tuesday, October 29th.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.